Allarity Therapeutics announced that it received notice from the NASDAQ Stock Market that it was granted a hearing before a Nasdaq Hearings Panel. This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq’s notification, disclosed in Allarity’s Form 8-K filed with the SEC on June 21, 2024, of Allarity’s non-compliance with Nasdaq Listing Rule 5550(a)(2), also known as the Bid-Price Rule. This rule requires that a company’s stock maintain a minimum bid price of $1.00 per share for at least 30 consecutive business days.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity Therapeutics Reports Promising Ovarian Cancer Trial Progress
- Allarity: Stenoparib continues to show clinical benefit in ovarian cancer
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
- Allarity Therapeutics Signs New Management Services Agreement
- Allarity regains compliance with Nasdaq minimum stockholder equity requirement